NYON, Switzerland--(BUSINESS WIRE)--Edwards Lifesciences today announced the launch in Europe of the SAPIEN 3 transcatheter pulmonary valve implantation (TPVI) system with Alterra adaptive prestent, ...
Irvine-based Edwards Lifesciences Corp.’s Sapien XT replacement transcatheter heart valve gained another approval this month. Edwards said the Food and Drug Administration granted it approval to use ...
SAPIEN 3, which showed superiority at 1 year, also demonstrates compelling outcomes equivalent to surgery at seven years SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (EW) today announced ...
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment of ...
Edwards Lifesciences has been awarded CE mark for the Sapien M3 mitral valve replacement system. The approval is for the transcatheter treatment of patients with symptomatic (moderate-to-severe or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results